These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25559742)

  • 41. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and biological evaluation of Isosteviol derivatives as FXa inhibitors.
    Shi Y; Pan BW; Li WC; Wang Q; Wu Q; Pan M; Fu HZ
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126585. PubMed ID: 31859158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors.
    Han Q; Dominguez C; Stouten PF; Park JM; Duffy DE; Galemmo RA; Rossi KA; Alexander RS; Smallwood AM; Wong PC; Wright MM; Luettgen JM; Knabb RM; Wexler RR
    J Med Chem; 2000 Nov; 43(23):4398-415. PubMed ID: 11087565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The design and synthesis of noncovalent factor Xa inhibitors.
    Quan ML; Wexler RR
    Curr Top Med Chem; 2001 Jun; 1(2):137-49. PubMed ID: 11899249
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.
    Xue T; Ding S; Guo B; Zhou Y; Sun P; Wang H; Chu W; Gong G; Wang Y; Chen X; Yang Y
    J Med Chem; 2014 Sep; 57(18):7770-91. PubMed ID: 25179681
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel factor Xa inhibitors based on a benzoic acid scaffold and incorporating a neutral P1 ligand.
    Nazaré M; Matter H; Klingler O; Al-Obeidi F; Schreuder H; Zoller G; Czech J; Lorenz M; Dudda A; Peyman A; Nestler HP; Urmann M; Bauer A; Laux V; Wehner V; Will DW
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2801-5. PubMed ID: 15125936
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How a β-D-glucoside side chain enhances binding affinity to thrombin of inhibitors bearing 2-chlorothiophene as P1 moiety: crystallography, fragment deconstruction study, and evaluation of antithrombotic properties.
    Belviso BD; Caliandro R; de Candia M; Zaetta G; Lopopolo G; Incampo F; Colucci M; Altomare CD
    J Med Chem; 2014 Oct; 57(20):8563-75. PubMed ID: 25268757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigation of the S3 site of thrombin: design, synthesis and biological activity of 4-substituted 3-amino-2-pyridones incorporating P1-argininals.
    Reiner JE; Lim-Wilby MS; Brunck TK; Ha-Uong T; Goldman EA; Abelman MA; Nutt RF; Semple JE; Tamura SY
    Bioorg Med Chem Lett; 1999 Mar; 9(6):895-900. PubMed ID: 10206557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards dual antithrombotic compounds - balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism.
    Ilić M; Dunkel P; Ilaš J; Chabielska E; Zakrzeska A; Mátyus P; Kikelj D
    Eur J Med Chem; 2013 Apr; 62():329-40. PubMed ID: 23376251
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.
    Al-Horani RA; Mehta AY; Desai UR
    Eur J Med Chem; 2012 Aug; 54():771-83. PubMed ID: 22770607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents.
    Ries UJ; Priepke HW; Hauel NH; Handschuh S; Mihm G; Stassen JM; Wienen W; Nar H
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2297-302. PubMed ID: 12824021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-
    Dolšak A; Bratkovič T; Mlinarič L; Ogorevc E; Švajger U; Gobec S; Sova M
    Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33804161
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selective boron-containing thrombin inhibitors--X-ray analysis reveals surprising binding mode.
    von Matt A; Ehrhardt C; Burkhard P; Metternich R; Walkinshaw M; Tapparelli C
    Bioorg Med Chem; 2000 Sep; 8(9):2291-303. PubMed ID: 11026541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tetrahydro-isoquinoline-based factor Xa inhibitors.
    Kucznierz R; Grams F; Leinert H; Marzenell K; Engh RA; von der Saal W
    J Med Chem; 1998 Dec; 41(25):4983-94. PubMed ID: 9836616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-
    Novichikhina N; Ilin I; Tashchilova A; Sulimov A; Kutov D; Ledenyova I; Krysin M; Shikhaliev K; Gantseva A; Gantseva E; Podoplelova N; Sulimov V
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32325823
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.
    Meneyrol J; Follmann M; Lassalle G; Wehner V; Barre G; Rousseaux T; Altenburger JM; Petit F; Bocskei Z; Schreuder H; Alet N; Herault JP; Millet L; Dol F; Florian P; Schaeffer P; Sadoun F; Klieber S; Briot C; Bono F; Herbert JM
    J Med Chem; 2013 Dec; 56(23):9441-56. PubMed ID: 24175584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel potent and selective thrombin inhibitors based on a central 1,4-benzoxazin-3(4H)-one scaffold.
    Ilas J; Tomasić T; Kikelj D
    J Med Chem; 2008 May; 51(9):2863-7. PubMed ID: 18412326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective and dual action orally active inhibitors of thrombin and factor Xa.
    Young RJ; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Hubbard JA; Kelly HA; Pateman AJ; Patikis A; Senger S; Shah GP; Toomey JR; Watson NS; Zhou P
    Bioorg Med Chem Lett; 2007 May; 17(10):2927-30. PubMed ID: 17420122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa.
    Klein SI; Czekaj M; Gardner CJ; Guertin KR; Cheney DL; Spada AP; Bolton SA; Brown K; Colussi D; Heran CL; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
    J Med Chem; 1998 Feb; 41(4):437-50. PubMed ID: 9484495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.